Update on Influenza and Malaria Programmes


 

TIDMLPX 
 
 
Lipoxen PLC 
28 April 2010 
 
? 
+---------------------------------+---------------------------------+ 
| FOR IMMEDIATE RELEASE           |                   28 April 2010 | 
+---------------------------------+---------------------------------+ 
 
 
 
                                  Lipoxen plc 
                          ('Lipoxen' or 'the Company') 
                   Update on Influenza and Malaria Programmes 
Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the 
development of high-value differentiated biologicals, vaccines and siRNA 
delivery, is pleased to report positive results  on two of its ImuXen 
proprietary candidates. 
Influenza Novel Vaccine Candidate 
Since being appointed in September 2009 as the lead member of the research and 
development consortium for the Technology Strategy Board controlled-release 
nanoparticle vaccine research programme (which includes Lipoxen's novel 
patent-protected influenza vaccine project) the Company has completed initial 
pre-clinical development and has successfully developed a number of viable 
vaccine candidates likely to induce effective immunity against influenza. 
Following the successful results of this programme, Lipoxen will now complete 
the necessary live influenza virus challenge studies using recognised and 
validated in vivo models.  In addition, the thermo-stable properties of the new 
formulations will also be investigated as the manufacturing process is expected 
to result in products that do not require refrigeration - which is a significant 
distribution and storage issue for modern vaccines. 
The consortium, which also includes the Health Protection Agency and the 
Multi-Imaging Centre at the University of Cambridge, will submit its Programme 
Report to the Technology Strategy Board in H2 2010. Lipoxen intends to seek a 
licence partner and expects to move the project into the clinic in 2011. 
PATH Malaria Vaccine Initiative 
Lipoxen's MVI project has now completed its experimental phase and the Company 
can report that Lipoxen delivered the formulation which utilizes Lipoxen's 
ImuXen  technology to enhance the liposomal delivery of malaria antigens to the 
immune system.  Preclinical tests revealed that anti-malaria antibodies were 
increased 10 fold using the liposomal co-delivery platform compared to the 
antibody response to a mixture of antigen-coding DNA plus protein antigen.  In 
addition, malaria antigen-specific CD4+ T cells were detected. 
 
Although MVI has decided not to commit additional funding to the project Lipoxen 
believes that the programme has further demonstrated the validity of the ImuXen 
platform and intends to seek a commercial partner to take this novel platform 
into clinical development. 
 
The Company looks forward to reporting further progress in due course. 
ImuXen  Platform Technology 
Lipoxen's proprietary ImuXen  technology is based on the use of natural 
substances found in the human body (lipids) to entrap the active ingredients 
(usually antigens) within liposomes to ensure their direct delivery to the 
appropriate cells of the immune system, thereby enhancing the effectiveness of 
vaccines by generating strong and broadly based immune responses. 
Commenting on these results, Scott Maguire, CEO said: "I am further encouraged 
that one of our leading technology platforms has again demonstrated its 
potential to underpin a new generation of vaccine products with enhanced 
performance characteristics. Along with increased efficacy, Lipoxen's 
refrigeration-free vaccines have the potential to solve yet another material 
issue in modern vaccines." 
For further information, please contact: 
Enquiries 
+------------------------------------------+--------------------+ 
| Lipoxen plc                              |     +44 (0)20 7389 | 
|                                          |               5015 | 
+------------------------------------------+--------------------+ 
| M. Scott Maguire, Chief Executive        |                    | 
| Officer                                  |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Singer Capital Markets (nominated        |     +44 (0)20 3205 | 
| adviser)                                 |               7500 | 
+------------------------------------------+--------------------+ 
| Jeff Keating / Claes Spång               |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Buchanan Communications                  |     +44 (0)20 7466 | 
|                                          |               5000 | 
+------------------------------------------+--------------------+ 
| Lisa Baderoon, Catherine Breen           |                    | 
+------------------------------------------+--------------------+ 
 
About Lipoxen 
Lipoxen plc is a biopharmaceutical company focused on the development of new and 
improved biologic drugs and vaccines.  Lipoxen has three proprietary patented 
technology platforms: 
 
1) PolyXen - for extending the efficacy and half life of biologic drugs 
2) ImuXen - for creating new vaccines and improving existing vaccines 
3) SiRNAblate - for the delivery of siRNA 
 
Lipoxen's technology is designed to improve the efficacy, safety, stability, 
biological half-life and immunologic characteristics of its products. 
 
Lipoxen has multiple drug and vaccine programmes in development.  Two products 
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a 
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes 
vaccines against HIV, influenza and malaria and an exclusive license deal with 
Baxter Healthcare for Factor VIII. 
 
The Company has a low-risk business model and out-licenses its proprietary 
technologies to biopharmaceutical companies that have strong manufacturing and 
marketing capabilities.  Lipoxen currently has commercial agreements with some 
of the world's leading biotechnology and pharmaceutical companies including 
Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and 
Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and 
management led the GBP2.9 million fundraising that the Company announced in May 
2009. This fundraising was followed up by a GBP1.2 million Placing in April 
2010. 
 
Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock 
Exchange under the ticker symbol LPX. More information can be found at the 
Company's website: www.lipoxen.com. 
 
About the Technology Strategy Board 
The Technology Strategy Board is a business-led executive non-departmental 
public body, established by the government.  Its role is to promote and support 
research into, and development and exploitation of, technology and innovation 
for the benefit of UK business, in order to increase economic growth and improve 
the quality of life.  It is sponsored by the Department for Business, Innovation 
and Skills (BIS).  For further information please visit www.innovateuk.org. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRASEFFLWFSSESL
Lipoxen (LSE:LPX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024